ERBB2 and breast cancer: The CECCY (Carvedilol Effect in Preventing Chemotherapy-Induced Cardiotoxicity) trial showed no significant changes in the LV ejection fraction during a six-month follow-up period in patients with HER-2–negative breast cancer.